CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Paves the way for next-gen ultra-precise gas sensing
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Subscribe To Our Newsletter & Stay Updated
